A detailed history of Advisors Asset Management, Inc. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Advisors Asset Management, Inc. holds 212,439 shares of BMY stock, worth $12.2 Million. This represents 0.21% of its overall portfolio holdings.

Number of Shares
212,439
Previous 163,302 30.09%
Holding current value
$12.2 Million
Previous $6.78 Million 62.11%
% of portfolio
0.21%
Previous 0.14%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$39.66 - $51.75 $1.95 Million - $2.54 Million
49,137 Added 30.09%
212,439 $11 Million
Q2 2024

Aug 14, 2024

BUY
$40.25 - $52.99 $1.17 Million - $1.55 Million
29,164 Added 21.74%
163,302 $6.78 Million
Q1 2024

May 14, 2024

BUY
$47.98 - $54.4 $2.04 Million - $2.31 Million
42,509 Added 46.39%
134,138 $7.27 Million
Q4 2023

Feb 14, 2024

BUY
$48.48 - $57.85 $501,089 - $597,937
10,336 Added 12.71%
91,629 $4.7 Million
Q2 2023

Aug 14, 2023

SELL
$63.71 - $70.74 $649,714 - $721,406
-10,198 Reduced 11.15%
81,293 $5.2 Million
Q1 2023

May 12, 2023

SELL
$65.71 - $74.53 $171,831 - $194,895
-2,615 Reduced 2.78%
91,491 $6.34 Million
Q4 2022

Feb 13, 2023

SELL
$68.48 - $81.09 $539,006 - $638,259
-7,871 Reduced 7.72%
94,106 $6.77 Million
Q3 2022

Nov 08, 2022

BUY
$0.13 - $76.84 $264 - $156,369
2,035 Added 2.04%
101,977 $7.25 Million
Q2 2022

Aug 08, 2022

BUY
$72.62 - $79.98 $185,035 - $203,789
2,548 Added 2.62%
99,942 $7.7 Million
Q1 2022

May 17, 2022

BUY
$61.48 - $73.72 $456,673 - $547,592
7,428 Added 8.26%
97,394 $7.11 Million
Q4 2021

Feb 15, 2022

BUY
$53.63 - $62.52 $469,530 - $547,362
8,755 Added 10.78%
89,966 $5.61 Million
Q3 2021

Nov 12, 2021

BUY
$59.17 - $69.31 $790,807 - $926,328
13,365 Added 19.7%
81,211 $4.81 Million
Q2 2021

Jul 30, 2021

BUY
$61.91 - $67.42 $778,827 - $848,143
12,580 Added 22.76%
67,846 $4.53 Million
Q1 2021

May 07, 2021

BUY
$59.34 - $66.74 $581,175 - $653,651
9,794 Added 21.54%
55,266 $3.49 Million
Q4 2020

Feb 12, 2021

BUY
$57.74 - $65.43 $316,415 - $358,556
5,480 Added 13.7%
45,472 $2.82 Million
Q3 2020

Nov 16, 2020

BUY
$57.43 - $63.64 $473,452 - $524,648
8,244 Added 25.97%
39,992 $2.41 Million
Q2 2020

Aug 12, 2020

BUY
$54.82 - $64.09 $115,012 - $134,460
2,098 Added 7.08%
31,748 $1.87 Million
Q1 2020

May 15, 2020

SELL
$46.4 - $67.43 $3.28 Million - $4.77 Million
-70,788 Reduced 70.48%
29,650 $1.65 Million
Q4 2019

Feb 14, 2020

BUY
$49.21 - $64.19 $399,486 - $521,094
8,118 Added 8.79%
100,438 $6.45 Million
Q3 2019

Nov 14, 2019

SELL
$42.77 - $50.71 $19,930 - $23,630
-466 Reduced 0.5%
92,320 $4.68 Million
Q2 2019

Aug 14, 2019

SELL
$44.62 - $49.34 $138,812 - $153,496
-3,111 Reduced 3.24%
92,786 $4.21 Million
Q1 2019

May 15, 2019

BUY
$45.12 - $53.8 $1.52 Million - $1.82 Million
33,762 Added 54.34%
95,897 $4.58 Million
Q4 2018

Jan 31, 2019

BUY
$48.76 - $63.23 $1.78 Million - $2.3 Million
36,445 Added 141.86%
62,135 $3.23 Million
Q3 2018

Nov 15, 2018

SELL
$55.19 - $62.25 $35,763 - $40,338
-648 Reduced 2.46%
25,690 $1.6 Million
Q2 2018

Aug 22, 2018

SELL
$50.53 - $62.98 $120,160 - $149,766
-2,378 Reduced 8.28%
26,338 $1.46 Million
Q2 2018

Aug 15, 2018

SELL
$50.53 - $62.98 $147,699 - $184,090
-2,923 Reduced 9.24%
28,716 $1.46 Million
Q1 2018

May 15, 2018

SELL
$59.92 - $68.98 $311,404 - $358,489
-5,197 Reduced 14.11%
31,639 $2.1 Million
Q4 2017

Feb 13, 2018

SELL
$59.94 - $65.35 $5.08 Million - $5.54 Million
-84,729 Reduced 69.7%
36,836 $2.26 Million
Q3 2017

Nov 07, 2017

BUY
$55.23 - $63.74 $6.71 Million - $7.75 Million
121,565
121,565 $7.75 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $122B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Advisors Asset Management, Inc. Portfolio

Follow Advisors Asset Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisors Asset Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisors Asset Management, Inc. with notifications on news.